Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another step closer. Good stuff.
Thanks Chris what do you think will happen to share price tomorrow? Surely got to have a positive impact?
Today was the formal release.
Thanks will this be formally released?
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
• DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model • Potential in Lung, Bloodstream and Urinary Tract Infections
• Activity Shown Against Resistant and Non-Resistant Strains
• Enterobacteriaceae are Gram-Negative Bacteria that Cause a Large
Number of Serious Infections
https://www.summitplc.com/app/uploads/2019/04/2019_RNS_17-ECCMID-data-FINAL.pdf
Link for the report:
https://www.summitplc.com/app/uploads/2019/04/Summit-Therapeutics_ECCMID_Final_12042019.pdf
After a great day on the Nasdaq! Let’s hope these close mid 30s by tomorrow close
Good to see NASDAQ is back to $2.00 = £0.31 on good volume I think that future events Summit will be attending this month & recent RNS's suggests the SP is now getting more traction as interest grows in Summit.Current SP is a bargain & I will be Buying in when my INFA shares finally recover back up to recent highs.
This sounds great expansion.
I am newer to the company buying last year and seeing it drop further but just topped up with another 5,000 shares at market close as I feel your faith is well placed. Antibiotics going to be an important part of big pharma making SUMM a target for a bid.
Good rns.....more value to add potentially.
Wasn’t expecting that. Strong and exciting news news that ceratainly could send the SP in the right direction. Plenty of value here at these prices. Good work SUMM.
Todays RNS is another example of the progress that Summit are making on its new platforms which will generate further shareholder value in the coming months & years.One day an RNS announcement will finally propel the SP northwards.GLA.
Summit Therapeutics advancing its pipeline of innovative antibiotics - Richard Pye:
https://www.proactiveinvestors.co.uk/companies/stocktube/12766/summit-therapeutics-advancing-its-pipeline-of-innovative-antibiotics-12766.html
Pharma ‘spews nonsense’ on antibiotic R&D: Jim O'Neill:
https://www.fiercebiotech.com/biotech/
https://www.bbc.com/news/health-47719269
Hope all are well
- EP
Seems like there should be some massive upside this year!
Financial Highlights
Chris make a good point below re paper profit and how they might fund raise but a great deal, excuse the pun, can happen in a year.....
The Financial Highlights encouraging imo.
Net proceeds of $24.4 million (£19.2 million) received from the sale of American Depositary Shares in a private placement that completed in January 2019.
Profit for the year ended 31 January 2019 of £7.5 million compared to a loss of £20.2 million for the year ended 31 January 2018.
Cash and cash equivalents at 31 January 2019 of £26.9 million compared to £20.1 million at 31 January 2018.
Todays RNS
It is good to see a profit was made but a 'paper profit' due to it being based on releasing deferred revenue for which most of the cash has already been received.Progress is clearly being made but the 'Elephant in the room' is still that a fund raise will be required in order to extend the cash run way beyond January 2020 as detailed below.Until the funding issue is resolved I cannot see how the SP can significantly improve this year.
Extract from the Notes to the Accounts:
'The Group is evaluating various options to finance its cash needs through a combination of some, or all, of the following: equity offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organisations and patient advocacy groups, debt financings, and marketing, distribution or licensing arrangements. Whilst the Group believes that funds would be available in this manner before the end of January 2020, there can be no assurance that the Group will be able to generate funds, on terms acceptable to the Group, on a timely basis or at all, which would impact the Group’s ability to continue as a going concern. The failure of the Group to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Group’s business, results of operations and financial condition.'
Summit Therapeutics Has Started Attracting Institutional Investors Again:
https://seekingalpha.com/article/4250804-summit-therapeutics-started-attracting-institutional-investors#alt1
http://www.lse.co.uk/sharecast-news-article.asp?ArticleCode=28787490&ArticleHeadline=Pfizer_buys_15_stake_in_French_gene_therapy_company_Vivet
One can hope, who knows a bit of antibiotic research might attract one of the big pharma?
I topped up my wife's shares today just to round up & Bought 245 shares which are showing as a Sell & should be a Buy.
Hopefully more good publicity at the Berlin Conference today and tomorrow. All my hopes for a recovery here are pinned on success with the novel antibiotics. Still can't believe we got so far down the road with the DMD trials only to be kicked in the goolies at the eleventh hour......
55Petition to ban shorting https://petition.parliament.uk/petitions/242399 Copied from BOO board
Potentially loads of possible news coming and if not then it will rise anyway as the drop from over £2 was overdone. This should be trading around £1 now but will be happy if it gradually gets there. Consolidation has taken place at this level now which is another good sign
This imminent 50% rise is based on what stew200? Is there some positive news that is due very soon for Summit?